Bromocriptine


Ergoline D2 dopamine receptor agonist

An ergoline-derived D2 receptor agonist; used in Parkinson disease, prolactinoma, and (off-label) for diabetes and obesity research.

Abstract

Bromocriptine (2-bromo-12′-hydroxy-2′-(1-methylethyl)-5′-alpha-(2-methylpropyl)ergotaman-3′,6′,18-trione; CAS 25614-03-3; molecular formula C32H40BrN5O5; molecular weight 654.59) is a semi-synthetic ergoline derivative developed at Sandoz and approved by the FDA in 1978 (Parlodel) for Parkinson disease and hyperprolactinemia. The compound is a high-affinity D2 dopamine receptor agonist (Ki approximately 5 nM) with secondary D1, alpha-adrenergic, and serotonergic effects. The dopaminergic activity in pituitary lactotrophs suppresses prolactin secretion (the prolactinoma indication); the activity in basal ganglia provides modest symptomatic relief in Parkinson disease (largely supplanted by levodopa and non-ergot agonists). A formulation released in the morning (Cycloset, FDA approved 2009) is approved for type 2 diabetes; the rationale is reset of the circadian dopaminergic peak and consequent metabolic improvement. Plasma half-life is 4 to 6 hours; metabolism is hepatic via CYP3A4. Used as a reference D2 agonist with broad receptor profile.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph